No Survival Benefit in Advanced Breast Cancer With Frontline CDK4/6 Inhibition

(MedPage Today) — Frontline treatment with a CDK4/6 inhibitor did not improve overall survival (OS) in advanced hormone receptor (HR)-positive/HER2-negative breast cancer compared with second-line treatment, updated results from a randomized trial…